Key Takeaways
- JPMorgan (JPM) significantly upgraded EasyJet (EZJ) to Neutral from Underweight, nearly doubling its price target to 715p from 360p on improved sector outlooks.
- China’s export growth remains resilient, expanding despite escalating trade tensions and new tariff threats from the United States.
- Cencora (COR) received a price target increase to $390 from $382 by JPMorgan following a robust fiscal third-quarter earnings beat and raised full-year guidance.
- EasyJet shares are benefiting from a combination of falling oil prices and a strategic pivot toward its high-margin Holidays segment.
JPMorgan Reverses Stance on EasyJet with Major Target Hike
In a notable shift in sentiment, JPMorgan (JPM) has upgraded EasyJet (EZJ) to Neutral from its previous Underweight rating. The investment bank more than doubled its price target for the airline, moving from 360p to 715p. This aggressive revision reflects a more constructive view of the European aviation sector as the carrier navigates a competitive leisure market.
The upgrade comes as EasyJet continues to leverage its EasyJet Holidays division, which has emerged as a significant growth pillar for the group. While analysts previously expressed concern over winter pricing pressures and high capacity growth in the UK, the current valuation—trading at approximately 7 times 2026 estimated earnings—is now viewed as an attractive entry point for investors seeking recovery plays in the travel sector.
China Exports Show Resilience Amid U.S. Trade Friction
Despite renewed tensions with Washington, China’s export growth continues to defy expectations. Recent data indicates that Chinese shipments to global markets remain robust, even as the U.S. administration considers expanded tariffs and trade restrictions. This resilience is largely attributed to China diversifying its trade partners and maintaining a dominant position in the global supply chain for green energy components and consumer electronics.
Market analysts note that the "robust" performance of Chinese exports provides a critical buffer for the world's second-largest economy, which is currently grappling with a sluggish domestic property market. However, investors remain cautious as the potential for a broader trade war persists, particularly with the U.S. eyeing stricter controls on high-tech exports and automotive imports.
Cencora Gains Momentum on Earnings Beat and Target Raise
Cencora (COR) is seeing renewed analyst confidence after delivering a strong fiscal third-quarter report. JPMorgan (JPM) raised its price target on the pharmaceutical distributor to $390, maintaining a positive outlook. The company reported adjusted earnings per share (EPS) of $4.48, surpassing the analyst consensus of $4.35, driven by high demand for specialty medicines and GLP-1 weight-loss drugs.
Following the results, Cencora raised its fiscal 2026 adjusted EPS guidance to a range of $17.75 to $17.95. The company's strategic acquisition of OneOncology in early 2026 has already begun to contribute to margin expansion. Furthermore, the board's decision to repurchase $1 billion in shares during the quarter underscores a commitment to returning capital to shareholders amidst steady revenue growth.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.